selected scholarly activity
-
conferences
- SAT0348 The Economic Value of Tofacitinib 5 Mg Bid in the Treatment of Moderate to Severe Rheumatoid Arthritis: A Canadian Analysis. Annals of the Rheumatic Diseases. 785.1-785. 2015
- The Economic Value of Tofacitinib 5 Mg Bid In The Treatment of Moderate To Severe Rheumatoid Arthritis: A Canadian Analysis. Value in Health. A160-A161. 2015
- COST UTILITY ANALYSIS OF BOTOX VS. ANTICHOLINERGIC MEDICATION FOR URINARY INCONTINENCE, DUE TO NEUROGENIC DETRUSOR OVERACTIVITY ASSOCIATED WITH SPINAL CORD INJURY OR MULTIPLE SCLEROSIS. Journal of Epidemiology and Community Health. A5.1-A5. 2015
- Screening For Type 2 Diabetes: A Methodological Review And Cost Analysis. Value in Health. A126-A126. 2014
- CHARACTERISTICS OF THE ABORIGINAL PEOPLE WITH DIABETES IN THE SOUTH-WESTERN OF ONTARIO, CANADA. Value in Health. A495-A496. 2012
- PDB34 Economic Evaluation of Treating Diabetes Patients According to Guidelines in South-Western Ontario, Canada. Value in Health. A499-A499. 2012
- PIN30 Economic Evaluation of a Cluster Randomized Controlled Trial of an Influenza Immunization Program Directed at Healthy Children. Value in Health. A242-A242. 2012
- PMD25 THE COST-UTILITY AND VALUE OF INFORMATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION COMPARED TO STANDARD MANAGEMENT AND SURGICAL AORTIC VALVE REPLACEMENT IN PATIENTS WITH SEVERE SYMPTOMATIC AORTIC VALVE STENOSIS. Value in Health. A83-A83. 2011
- HEALTH STATUS, PHYSICIAN, DAY PROCEDURES AND HOPITALIZATION COSTS ASSOCIATED WITH RHEUMATOID-ARTHRITIS IN ONTARIO. Value in Health. A133-A133. 2010
- PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE. Value in Health. A73-A73. 2010
- PRS7 TRIPLE THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Value in Health. A197-A197. 2010
- PSY30 COST-EFFECTIVENESS OF BARIATRIC SURGICAL PROCEDURES VERSUS NO TREATMENT FOR MORBID OBESITY. Value in Health. A211-A211. 2010
- UTILIZING HEALTH SURVEY AND ADMINISTRATIVE DATA TO ESTIMATE THE BURDEN OF OSTEO-ARTHRITIS IN ONTARIO. Value in Health. A133-A134. 2010
- DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES. Value in Health. A234-A234. 2009
- MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R. Value in Health. A226-A227. 2009
- PDB21 WHO ARE THEY FOOLING?: COST OF DISEASE OR COMPLICATIONS CAN SIGNIFICANTLY BIAS ESTIMATES UNLESS CONTROL (NON-DISEASED) COSTS ARE NOT ALSO ACCOUNTED FOR IN THE ANALYSIS. Value in Health. A405-A405. 2009
- PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE. Value in Health. A346-A346. 2009
- PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS: A SYSTEMATIC REVIEW. Value in Health. A252-A252. 2009
- PND46 A SYSTEMATIC REVIEW AND META-ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP. Value in Health. A374-A374. 2009
- PSY18 THE BURDEN OF OBESITY IN ONTARIO. Value in Health. A378-A378. 2009
- PSY30 COST-UTILITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) COMPARED WITH CORTICOSTEROIDS FOR THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IN CANADA. Value in Health. A380-A381. 2009
- PGI6 COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR REFRACTORY ULCERATIVE COLITIS. Value in Health. A58-A58. 2009
- QL3 ESTIMATION OF UTILITY VALUES FOR DIABETESXD-RELATED COMPLICATIONS ON QUALITY OF LIFE FOR PATIENTS WITH TYPE-2 DIABETES IN ONTARIO, CANADA. Value in Health. A17-A17. 2009
- PGI7 COST EFFECTIVENESS ANALYSIS OF HELICOBACTER PYLORI SCREENING IN PREVENTION OF GASTRIC CANCER IN CHINESE. Value in Health. A85-A86. 2008
- PHP74 THE CADTH GUIDELINES FORTHE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: DO CURRENT CANADIAN ECONOMIC EVALUATIONS PASS THE TEST?. Value in Health. A51-A51. 2008
- PMC15 DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS. Value in Health. A173-A174. 2008
- PCV77 DISCRETE-EVENT-SIMULATION AN APPROACH THAT CHALLENGES TRADITIONAL MODELING METHODS? AN ILLUSTRATION USING DRUG-ELUTING STENTS. Value in Health. A361-A361. 2006
- The cost-effectiveness of calcium and Vitamin D or hormone replacement therapy in the prevention of osteoporotic fractures in Canadian postmenopausal women.. Journal of Bone and Mineral Research. S279-S279. 2006
- CE4 COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES) COMPARED TO BARE METAL STENTS (BMS) USING “REAL WORLD” DATA. Value in Health. A8-A8. 2006
- PDB10 MODELLING LIFETIME HEATLH CARE COSTS AND CONSEQUENCES OF A NURSE-LED MULTIFACETED INTERVENTION TO IMPROVE THE MANAGEMENT OF PATIENTS WITH DIABETES: RESULTS FROM A COMPUTERIZED SIMULATION MODEL. Value in Health. A33-A34. 2006
- PDB19 IMPROVING THE MEASUREMENT OF THE COST OF DIABETES-RELATED COMPLICATIONS: RESULTS FROM A LARGE PROSPECTIVE COHORT STUDY. Value in Health. A36-A36. 2006
- PMC1 TRANSFERABILITY OF ECONOMIC EVALUATIONS: CAN RESULTS FROM ONE GEOGRAPHIC AREA BE USED TO HELP INFORM HEALTH CARE DECISION MAKING IN ANOTHER?. Value in Health. A56-A56. 2006
- PSU1 COST-UTILTY OF ELECTIVE ENDOVASCULAR REPAIR (EVAR) COMPARED TO OPEN SURGICAL REPAIR (OSR) OF ABDOMINAL AORTIC ANEURYSMS (AAA). Value in Health. A173-A173. 2006
- Photodynamic therapy (PDT) for Barrett's esophagus with high-grade dysplasia (BE+HGD): Cost-effectiveness model with probabilistic sensitivity analysis. Gastrointestinal Endoscopy. AB137-AB137. 2004
- Trickery, deception and economic evaluations: Is there more harm than good?. Osteoporosis International. S105-S105. 2004
- The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women.. Journal of Bone and Mineral Research. S384-S384. 2003
- Probabilistic cost-effectiveness analyses of long term management therapies for postmenopausal osteoporosis: Cautions and concerns of results obtained from traditional deterministic sensitivity analyses. Osteoporosis International. S16-S17. 2003
- The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women. Osteoporosis International. S84-S85. 2003
- A Note on the Estimation of Confidence Intervals for Cost-Effectiveness When Costs and Effects Are Censored. Medical decision making. 173-177. 2002
- The effect of clinical risk stratification on the cost-effectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study. Circulation. 345-345. 2001
- Cost-effectiveness of the implantable cardioverter defibrillator: Results from the Canadian Implantable Defibrillator Study (CIDS). Journal of the American College of Cardiology. 152A-153A. 2000
- Economic evaluation of donepezil for treatment of Alzheimer's disease in Canada. Medical decision making. 482-482. 1998
- Economic evaluation of donepezil (D) for Alzheimer's disease in Canada.. Clinical Pharmacology and Therapeutics. 196-196. 1998
-
journal articles
- The premarket assessment of the cost-effectiveness of a predictive technology “Straticyte™” for the early detection of oral cancer: a decision analytic model. Health Economics Review. 7:35. 2017
- Estimates of health utility scores in chronic kidney disease. Geriatric Nephrology and Urology. 49:2043-2049. 2017
- Low-intensity pulsed ultrasound for treatment of tibial fractures. The Bone & Joint Journal. 99-B:1526-1532. 2017
- Low-intensity pulsed ultrasound for treatment of tibial fractures AN ECONOMIC EVALUATION OF THE TRUST STUDY. The Bone & Joint Journal. 99B:1526-1532. 2017
- Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ open. 5:E653-E661. 2017
- Preliminary Results of the Adoption and Application of the Integrated Comprehensive Care Bundle Care Program When Treating Patients with Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal. 2017:1-10. 2017
- The Integrated Comprehensive Care Program: A Novel Home Care Initiative After Major Thoracic Surgery. Seminars in Thoracic and Cardiovascular Surgery. 28:574-582. 2016
- Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations. BMC Research Notes. 8:244. 2015
- Do different decision-analytic modeling approaches produce different results? A systematic review of cross-validation studies. Expert Review of Pharmacoeconomics and Outcomes Research. 15:451-463. 2015
- Capsule Endoscopy in the Assessment of Obscure Gastrointestinal Bleeding: An Economic Analysis.. Ontario Health Technology Assessment Series. 15:1-32. 2015
- Colon Capsule Endoscopy for the Detection of Colorectal Polyps: An Economic Analysis.. Ontario Health Technology Assessment Series. 15:1-43. 2015
- Incorporating ulipristal acetate in the care of symptomatic uterine fibroids: a Canadian cost-utility analysis of pharmacotherapy management. ClinicoEconomics and Outcomes Research. 7:213-213. 2015
- Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU) for Treatment of Symptomatic Uterine Fibroids: An Economic Analysis.. Ontario Health Technology Assessment Series. 15:1-61. 2015
- ECONOMIC EVALUATION OF AN INFLUENZA IMMUNIZATION STRATEGY OF HEALTHY CHILDREN. International Journal of Technology Assessment in Health Care. 30:394-399. 2014
- Point-of-Care Hemoglobin A1c Testing: A Budget Impact Analysis.. Ontario Health Technology Assessment Series. 14:1-23. 2014
- Cost-effectiveness of 64-slice CT angiography compared to conventional coronary angiography based on a coverage with evidence development study in Ontario. Expert Review of Pharmacoeconomics and Outcomes Research. 13:675-690. 2013
- Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: A Canadian perspective. Journal of Thoracic and Cardiovascular Surgery. 146:52-60.e3. 2013
- Cost-Effectiveness of Catheter Ablation for Rhythm Control of Atrial Fibrillation. International Journal of Vascular Medicine. 2013:1-11. 2013
- Cost-effectiveness of the carbon-13 urea breath test for the detection of Helicobacter pylori: an economic analysis.. Ontario Health Technology Assessment Series. 13:1-28. 2013
- The excess burden of rheumatoid arthritis in Ontario, Canada.. Clinical and Experimental Rheumatology. 31:18-24. 2013
- Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence update.. Ontario Health Technology Assessment Series. 13:1-40. 2013
- Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. Journal of Interventional Cardiac Electrophysiology. 35:259-275. 2012
- Cost-effectiveness of a shared computerized decision support system for diabetes linked to electronic medical records. Journal of the American Medical Informatics Association : JAMIA. 19:341-345. 2012
- Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease. Journal of Crohn's and Colitis. 6:77-85. 2012
- Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses.. CADTH technology overviews. 2:e2101. 2012
- Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.. Journal of Population Therapeutics and Clinical Pharmacology. 19:e166-e178. 2012
- Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model.. Ontario Health Technology Assessment Series. 12:1-61. 2012
- Epilepsy care in ontario: an economic analysis of increasing access to epilepsy surgery.. Ontario Health Technology Assessment Series. 12:1-41. 2012
- Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B).. Ontario Health Technology Assessment Series. 12:1-62. 2012
- Using health technology assessment to support evidence-based decision-making in Canada: an academic perspective. Expert Review of Pharmacoeconomics and Outcomes Research. 11:513-521. 2011
- Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Quality of Life Research. 20:939-943. 2011
- Economic Evaluation of Reamed versus Unreamed Intramedullary Nailing in Patients with Closed and Open Tibial Fractures: Results from the Study to Prospectively Evaluate Reamed Intramedullary Nails in Patients with Tibial Fractures (SPRINT). Value in Health. 14:450-457. 2011
- Triple Therapy for the Management of COPD: A Review. COPD: Journal of Chronic Obstructive Pulmonary Disease. 8:206-243. 2011
- Should Endovascular Repair Be Reimbursed for Low Risk Abdominal Aortic Aneurysm Patients? Evidence from Ontario, Canada. International Journal of Vascular Medicine. 2011:1-10. 2011
- General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. Expert Review of Pharmacoeconomics and Outcomes Research. 10:379-384. 2010
- Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario. Value in Health. 13:S8-S11. 2010
- Pharmacologic management of neovascular age-related macular degeneration: systematic review of economic evidence and primary economic evaluation. Canadian Journal of Ophthalmology. 45:223-230. 2010
- A Review of Methods Used in Long-Term Cost-Effectiveness Models of Diabetes Mellitus Treatment. PharmacoEconomics (Auckland). 28:255-277. 2010
- Patient outcomes after anti TNF-α drugs for Crohn’s disease. Expert Review of Pharmacoeconomics and Outcomes Research. 10:163-175. 2010
- Impact of the 1997 Canadian Guidelines on the Conduct of Canadian-Based Economic Evaluations in the Published Literature. Value in Health. 13:328-334. 2010
- Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.. Open Medicine. 4:e154-e166. 2010
- Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada. Cost Effectiveness and Resource Allocation. 8:14-14. 2010
- Cost Analysis of Multiplex PCR Testing for Diagnosing Respiratory Virus Infections. Journal of Clinical Microbiology. 47:2812-2817. 2009
- Approaches for Economic Evaluations of Health Care Technologies. Journal of the American College of Radiology. 6:307-316. 2009
- Conditionally Funded Field Evaluations and Practical Trial Design Within a Health Technology Assessment Framework. Journal of the American College of Radiology. 6:324-331. 2009
- Health Technology Assessment and Primary Data Collection for Reducing Uncertainty in Decision Making. Journal of the American College of Radiology. 6:332-342. 2009
- Illustrating Economic Evaluation of Diagnostic Technologies: Comparing Helicobacter pylori Screening Strategies in Prevention of Gastric Cancer in Canada. Journal of the American College of Radiology. 6:317-323. 2009
- Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in canadian adults with chronic immune thrombocytopenic purpura. Clinical Therapeutics. 31:1082-1091. 2009
- Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care. 25:196-207. 2009
- In search of the evidentiary foundation of published Canadian economic evaluations (2001–06). International Journal of Technology Assessment in Health Care. 25:214-221. 2009
- A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada. Value in Health. 12:245-252. 2009
- Paclitaxel Versus Sirolimus Stents in Diabetic and Nondiabetic Patients. Circulation. Cardiovascular Quality and Outcomes. 2:96-107. 2009
- Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Effectiveness and Resource Allocation. 7:20-20. 2009
- Excess Risk of Mortality and Complications Associated with Newly Diagnosed Cases of Diabetes in Ontario, Canada. Canadian Journal of Diabetes. 33:93-104. 2009
- Prevalence, Total and Excess Costs of Diabetes and Related Complications in Ontario, Canada. Canadian Journal of Diabetes. 33:35-45. 2009
- Reply. Journal of Vascular Surgery. 49:277-278. 2009
- Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada. Journal of Vascular Surgery. 48:779-787. 2008
- Economic evaluations conducted by Canadian health technology assessment agencies: Where do we stand?. International Journal of Technology Assessment in Health Care. 24:437-444. 2008
- Universal or Targeted Screening for Fetal Alcohol Exposure: A Cost-Effectiveness Analysis. Journal of Studies on Alcohol and Drugs. 69:510-519. 2008
- Assessing the Impact of Censoring of Costs and Effects on Health-Care Decision-Making: an Example Using the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Value in Health. 11:365-375. 2008
- Cost-effectiveness of reducing wait times for cataract surgery in Ontario. Canadian Journal of Ophthalmology. 43:213-217. 2008
- Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. International Journal of Technology Assessment in Health Care. 24:87-95. 2008
- Effects of study design and trends for EVAR versus OSR. Vascular Health and Risk Management. Volume 4:1011-1022. 2008
- Effectiveness and Safety of Drug-Eluting Stents in Ontario. New England Journal of Medicine. 357:1393-1402. 2007
- Managing multiple projects: a literature review of setting priorities and a pilot survey of healthcare researchers in an academic setting.. Perspectives in health information management / AHIMA, American Health Information Management Association. 4:4. 2007
- Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another. Current Medical Research and Opinion. 23:671-682. 2007
- Photodynamic Therapy for Barrett’s Esophagus with High-Grade Dysplasia: A Cost-Effectiveness Analysis. Canadian Journal of Gastroenterology and Hepatology. 21:217-222. 2007
- Cost-effectiveness of alternative treatments for women with osteoporosis in Canada. Current Medical Research and Opinion. 22:1425-1436. 2006
- Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. American Heart Journal. 151:1180-1185. 2006
- Economic Evaluation of Rivastigmine in Patients with Parkinson??s Disease Dementia. PharmacoEconomics (Auckland). 24:93-106. 2006
- The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion. 21:2017-2028. 2005
- Cost-effectiveness of physiologic pacing: Results of the Canadian Health Economic Assessment of Physiologic Pacing. Heart Rhythm. 2:270-275. 2005
- Cost-Effectiveness of Rhythm versus Rate Control in Atrial Fibrillation. ACP journal club. 141:653-653. 2004
- Principles of good modeling practice in healthcare cost-effectiveness studies. Expert Review of Pharmacoeconomics and Outcomes Research. 4:189-198. 2004
- A view from the bridge: agreement between the SF‐6D utility algorithm and the Health Utilities Index. Health Economics. 12:975-981. 2003
- Methods for Patient-Level Costing in the VA System: Are they Applicable to Canada?. Medical Care Research and Review. 60:142S-145S. 2003
- Methods for patient-level costing in the VA system: Are they applicable to Canada?. Medical Care Research and Review. 60:142S-145S. 2003
- Oseltamivir for Treatment of Influenza in Healthy Adults: Pooled Trial Evidence and Cost-Effectiveness Model for Canada. Value in Health. 6:116-125. 2003
- Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease. Medical decision making. 22:290-308. 2002
- Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Value in Health. 5:312-328. 2002
- Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease. Medical decision making. 22:290-308. 2002
- Thinking Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty in Cost-Effectiveness Studies. Annual Review of Public Health. 23:377-401. 2002
- A Note on the Estimation of Confidence Intervals for Cost-Effectiveness When Costs and Effects Are Censored. Medical decision making. 22:173-177. 2002
- Cost-Effectiveness of Screening Swab or Urine Specimens for Chlamydia trachomatis From Young Canadian Women in Ontario. Sexually Transmitted Diseases. 28:701-709. 2001
- Effect of Clinical Risk Stratification on Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. Circulation. 104:1622-1626. 2001
- Cost-Effectiveness of the Implantable Cardioverter-Defibrillator. Circulation. 103:1416-1421. 2001
- Cost Effectiveness in Canada of a Multidrug Prepackaged Regimen (Hp-PAC??)* for Helicobacter pylori Eradication. PharmacoEconomics (Auckland). 19:831-843. 2001
- Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. American Heart Journal. 139:423-429. 2000
- Economic Evaluation of Outpatient Treatment With Low-Molecular-Weight Heparin for Proximal Vein Thrombosis. JAMA Internal Medicine. 159:2298-2304. 1999
- The Economic Burden of Schizophrenia in Canada. Canadian Journal of Psychiatry. 44:464-472. 1999
- The Valuation of Productivity Costs Due to Premature Mortality: A Comparison of the Human-Capital and Friction-Cost Methods for Schizophrenia. Canadian Journal of Psychiatry. 44:455-463. 1999
- Economic Evaluation of Donepezil for the Treatment of Alzheimer's Disease in Canada. Journal of The American Geriatrics Society. 47:570-578. 1999
- Economic Evaluation of Long Term Management Strategies for Erosive Oesophagitis. PharmacoEconomics (Auckland). 16:679-697. 1999
- Hospital Selection for Unit Cost Estimates in Multicentre Economic Evaluations. PharmacoEconomics (Auckland). 15:561-572. 1999
- Induction of labour versus expectant management for prelabour rupture of the membranes at term: an economic evaluation. CANADIAN MEDICAL ASSOCIATION JOURNAL. 157:1519-1525. 1997
- Induction of labour versus expectant management for prelabour rupture of the membranes at term: an economic evaluation. TERMPROM Study Group. Term Prelabour Rupture of the Membranes.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 157:1519-1525. 1997